HOME >> MEDICINE >> NEWS
Data showed improved quality of life and patient satisfaction with SYMBICORT

Wilmington, DE May 22, 2007 New data demonstrated that the combination asthma therapy, SYMBICORT (budesonide/formoterol fumarate dihydrate), led to significant improvements in health-related quality of life (HRQL) and greater patient-reported satisfaction with asthma treatment, versus its monocomponents (budesonide or formoterol) or placebo. The results from these two 12-week randomized, double-blind trials were presented at the American Thoracic Society (ATS) 2007 International Conference held in San Francisco, May 18-23.

"Asthma is a chronic disease that can have a significant effect on patients' day-to-day routine, including participating in activities, such as walking to the store or even playing with their children," said Dr. Kevin R. Murphy, Clinical Professor, University of Nebraska Medical Center. "For the millions of asthma sufferers in the U.S., and especially for those whose condition is not adequately controlled with their current medication, SYMBICORT will provide a new option for patients to help manage and control their asthma, allowing them to get back to their daily activities."

SYMBICORT is a recently approved, combination therapy indicated for the long-term maintenance treatment of asthma in patients 12 years of age and older. SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma. Studies of patients treated with SYMBICORT demonstrated clinically significant improvement in lung function occurring within 15 minutes of beginning treatment. SYMBICORT has safety data in long-term studies of up to one year, and has a robust cardiac safety profile.

"The studies presented at this year's ATS conference provided valuable data on asthma control and asthma-related quality of life with SYMBICORT," said Chris O'Brien, Senior Director, Medical Science, AstraZeneca. "Asthma sufferers will have a new, rapid-acting combination treatment to help them achieve asthma control."

Administere
'"/>

Contact: Tracy Knudsen
Tracy.Knudsen@astrazeneca.com
302-885-1933
AstraZeneca
22-May-2007


Page: 1 2 3

Related medicine news :

1. New analysis showed UC patients in clinical remission had higher rates of employment
2. ROZEREM (ramelteon) showed significant reduction in time to fall asleep
3. New study showed ramelteon helped adults with chronic insomnia fall asleep, sleep longer
4. LSUHSC awarded designation resulting in improved patient safety and outcomes
5. ACP supports improved access to information on relative strengths and weaknesses
6. Performance-related financial incentives for hospitals not linked with improved quality of care
7. Investigational nonstimulant Guanfacine XR significantly improved child, adolescent ADHD symptoms
8. Alzheimers weight gain initiative also improved patients intellectual abilities
9. Acute coronary syndrome therapy improvements linked with fewer deaths and improved clinical outcomes
10. New study reports improved treatment and reduced mortality for patients with heart failure
11. Lymph node evaluation linked to improved survival for colon cancer patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2017)... ... 2017 , ... Global Lyme Alliance (GLA), the leading 501(c)(3) ... today announced the appointment of Timothy J. Sellati, Ph.D. as its Chief Scientific ... 20 years of research experience with Lyme and other tick-borne diseases. He has ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process ... 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , ... wrong, run afoul of The Quality System Regulation (§820.250), and Devicemakers find themselves ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, Keeping Up ... , In the competitive world of drug and device marketing and promotion, drug ... FDA rules. , The FDA has issued two draft guidances that are the ...
(Date:9/21/2017)... ... , ... Bill Howe Plumbing’s mission is to create an employee friendly company, ... For over 37 years, they have operated with their mission at the foundation and ... Diego. They were chosen as the Best San Diego plumber in 2016, named a ...
(Date:9/21/2017)... ... September 21, 2017 , ... The New England Center for ... today the election of Yie-Hsin Hung to the Board of Directors. , “The ... of Directors. Ms. Hung is an invaluable addition to our team,” said Vincent Strully, ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... 2017  ValGenesis Inc., the global leader in ... to announce the appointment of Dr. Ajaz ... of Directors and Chairman of Advisory Board beginning ... companies to manage their entire validation lifecycle process ... this process. Furthermore, ValGenesis VLMS enables rigorous compliance, ...
(Date:9/7/2017)... Sept. 7, 2017  Eli Lilly and Company ... to streamline operations to more efficiently focus resources ... cost structure. Global workforce reductions, including those from ... to impact approximately 3,500 positions. ... annualized savings of approximately $500 million that will ...
Breaking Medicine Technology:
Cached News: